Publications by authors named "K Zhdanov"
Background: The most severe complications of antibiotic use are clostridial infection (CDI) and pseudomembranous colitis (PMC). There is a need for further study of these conditions and identification of their triggers.
Aim: To identify risk factors for severe forms of antibiotic-associated diarrhea caused by .
Aim: To evaluate the efficacy and safety of riamilovir in the treatment of COVID-19 in adults.
Materials And Methods: The study included 180 patients with a laboratory-confirmed diagnosis of COVID-19 which fully meet the criteria for inclusion, non-inclusion and exclusion, signed a voluntary informed consent to participate in a clinical trial.
Results: The efficacy, good tolerability and safety of the drug riamilovir in the treatment of COVID-19 have been established.
Aim: Evaluation of the efficacy and safety of riamilovir as a drug for the prevention of coronavirus infection (COVID-19) in adults who have constant contact with COVID-19 patients as a result of living together.
Materials And Methods: The study included 750 adult participants living with patients with confirmed polymerase chain reaction method COVID-19, who had a negative polymerase chain reaction result for the SARS-CoV-2 virus at the initial level, met the criteria for inclusion, non-inclusion and exclusion, and signed a voluntary informed consent to participate in a clinical trial.
Results: The efficacy, good tolerability and safety of the drug riamilovir for the prevention of COVID-19 infection among people who have come into contact with COVID-19 patients in a family focus of infection have been established.
Article Synopsis
- * A study analyzed 696 URT samples from 285 COVID-19 patients and 100 healthy controls, revealing significant differences in microbial composition, with COVID-19 patients showing reduced abundance of 16 bacterial genera and unique taxa not found in healthy individuals.
- * As COVID-19 patients underwent treatment, certain depleted bacteria (like Fusobacterium and Neisseria) increased, suggesting recovery as their URT microbiome composition began resembling that of healthy individuals, indicating a shift towards stability.
Aim: To evaluate the clinical efficacy and safety of antiviral drug riamilovir in patients with acute respiratory viral infections (ARVI) of non-coronavirus (SARS-CoV-2) etiology with different dosing regimens.
Materials And Methods: The study included 150 patients with ARVI aged 18-27 years (50 patients received riamilovir in the regimen of 250 mg 3 times a day for 5 days, 50 patients received riamilovir in the regimen of 250 mg 5 times a day for 5 days, 50 patients received only pathogenetic treatment).
Results: The use of riamilovir in both treatment regimens led to a reduction in the duration of inpatient treatment.